Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.
2.

Estimating sensitivity and sojourn time in screening for colorectal cancer: a comparison of statistical approaches.

Prevost TC, Launoy G, Duffy SW, Chen HH.

Am J Epidemiol. 1998 Sep 15;148(6):609-19.

PMID:
9753016
3.

Estimation of screening test (Hemoccult) sensitivity in colorectal cancer mass screening.

Jouve JL, Remontet L, Dancourt V, Lejeune C, Benhamiche AM, Faivre J, Esteve J.

Br J Cancer. 2001 Jun 1;84(11):1477-81.

5.

Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends.

Telesca D, Etzioni R, Gulati R.

Biometrics. 2008 Mar;64(1):10-9. Epub 2007 May 14.

PMID:
17501937
6.

Estimating mean sojourn time and screening sensitivity using questionnaire data on time since previous screening.

Weedon-Fekjaer H, Lindqvist BH, Vatten LJ, Aalen OO, Tretli S.

J Med Screen. 2008;15(2):83-90. doi: 10.1258/jms.2008.007071.

PMID:
18573776
7.

The University of Rochester model of breast cancer detection and survival.

Hanin LG, Miller A, Zorin AV, Yakovlev AY.

J Natl Cancer Inst Monogr. 2006;(36):66-78.

PMID:
17032896
8.

A novel form of ascertainment bias in case-control studies of cancer screening.

Church TR.

J Clin Epidemiol. 1999 Sep;52(9):837-47.

PMID:
10529025
9.

Epidemiological aspects of cancer screening in Germany.

Becker N.

J Cancer Res Clin Oncol. 2003 Dec;129(12):691-702. Epub 2003 Oct 14.

PMID:
14557878
10.

An early- and late-stage convolution model for disease natural history.

Pinsky PF.

Biometrics. 2004 Mar;60(1):191-8.

PMID:
15032789
11.

Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends.

Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, Feuer EJ.

J Natl Cancer Inst. 2002 Jul 3;94(13):981-90.

PMID:
12096083
12.

Estimation of age-specific sensitivity and sojourn time in breast cancer screening studies.

Cong XJ, Shen Y, Miller AB.

Stat Med. 2005 Oct 30;24(20):3123-38.

PMID:
15977269
13.

The MISCAN-Fadia continuous tumor growth model for breast cancer.

Tan SY, van Oortmarssen GJ, de Koning HJ, Boer R, Habbema JD.

J Natl Cancer Inst Monogr. 2006;(36):56-65.

PMID:
17032895
14.

Overdiagnosis, sojourn time, and sensitivity in the Copenhagen mammography screening program.

Olsen AH, Agbaje OF, Myles JP, Lynge E, Duffy SW.

Breast J. 2006 Jul-Aug;12(4):338-42.

PMID:
16848843
15.

[Epidemiology and screening of colorectal cancer].

Dancourt V, Faivre J.

Rev Prat. 2004 Jan 31;54(2):135-42. French.

PMID:
15086055
16.

[Detection of cancer, sensitivity of the test and sensitivity of the screening program].

Launoy G, Duffy SW, Prevost TC, Bouvier V.

Rev Epidemiol Sante Publique. 1998 Nov;46(5):420-6. French.

PMID:
9864771
17.

Comparison of observed and expected numbers of detected cancers in the research center for cancer prevention and screening program.

Hamashima C, Sobue T, Muramatsu Y, Saito H, Moriyama N, Kakizoe T.

Jpn J Clin Oncol. 2006 May;36(5):301-8. Epub 2006 May 30.

PMID:
16735372
18.

A simulation model for evaluating the medical and economic outcomes of screening strategies for colorectal cancer.

Lejeune C, Arveux P, Dancourt V, Fagnani F, Bonithon-Kopp C, Faivre J.

Eur J Cancer Prev. 2003 Feb;12(1):77-84.

PMID:
12548114
19.

Impact of mammography on U.S. breast cancer mortality, 1975-2000: are intermediate outcome measures informative?

Habbema JD, Tan SY, Cronin KA.

J Natl Cancer Inst Monogr. 2006;(36):105-11.

PMID:
17032900
20.

Cancer incidence and mortality in France over the period 1978-2000.

Remontet L, Estève J, Bouvier AM, Grosclaude P, Launoy G, Menegoz F, Exbrayat C, Tretare B, Carli PM, Guizard AV, Troussard X, Bercelli P, Colonna M, Halna JM, Hedelin G, Macé-Lesec'h J, Peng J, Buemi A, Velten M, Jougla E, Arveux P, Le Bodic L, Michel E, Sauvage M, Schvartz C, Faivre J.

Rev Epidemiol Sante Publique. 2003 Feb;51(1 Pt 1):3-30.

Supplemental Content

Support Center